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selenium on rate of decline in lung function
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Kathryn B Arnold8, John J Crowley8, JoAnn Hartline8, Phyllis J Goodman8, Catherine M Tangen5,
Lori M Minasian9, Scott M Lippman10† and Eric Klein11†Abstract
Background: The intake of nutrients with antioxidant properties is hypothesized to augment antioxidant defenses,
decrease oxidant damage to tissues, and attenuate age-related rate of decline in lung function. The objective was
to determine whether long-term intervention with selenium and/or vitamin E supplements attenuates the annual
rate of decline in lung function, particularly in cigarette smokers.
Methods: The Respiratory Ancillary Study (RAS) tested the single and joint effects of selenium (200 μg/d
L-selenomethionine) and vitamin E (400 IU/day all rac-α-tocopheryl acetate) in a randomized double-blind placebo-
controlled trial. At the end of the intervention, 1,641 men had repeated pulmonary function tests separated by an
average of 3 years. Linear mixed-effects regression models estimated the effect of intervention on annual rate of
decline in lung function.
Results: Compared to placebo, intervention had no main effect on either forced expiratory volume in the first
second (FEV1) or forced expiratory flow (FEF25–75). There was no evidence for a smoking by treatment interaction
for FEV1, but selenium attenuated rate of decline in FEF25–75 in current smokers (P = 0.0219). For current smokers
randomized to selenium, annual rate of decline in FEF25–75 was similar to the annual decline experienced by never
smokers randomized to placebo, with consistent effects for selenium alone and combined with vitamin E.
Conclusions: Among all men, there was no effect of selenium and/or vitamin E supplementation on rate of lung
function decline. However, current smokers randomized to selenium had an attenuated rate of decline in FEF25–75, a
marker of airflow.
Trial registration: Clinicaltrials.gov identifier: NCT00241865.
Keywords: Spirometry, Vitamin E, Selenium, Forced expiratory volume, Forced expiratory flow rateBackground
Pulmonary function, which is reliably measured by spir-
ometry, is central to the diagnosis and staging of chronic
obstructive pulmonary disease (COPD). COPD, the third
most common cause of death in the US, led to $29.5B in
direct costs and $20B in lost productivity costs in 2010
[1]. The age-related rate of decline in the forced expira-
tory volume in the first second (FEV1) is a marker of* Correspondence: pac6@cornell.edu
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reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.mortality risk in the general population [2] and in
healthy smokers [3], the rate of decline is steeper in
smokers [4] and in COPD patients, although the latter
association varies by disease attributes [5,6]. The forced
expiratory flow at the mid-portion of forced vital cap-
acity (FEF25–75) reflects the state of small airways, and
offers a measure of lung function reflecting airflow ra-
ther than volume [7]. Attenuating lung function decline
may reduce morbidity and mortality, both in healthy
persons and in COPD patients. The identification of fac-
tors that affect lung function decline is important to the
development of clinical or public health interventions.
Both smoking and aging accelerate the annual rate of
decline in FEV1 [4,8]; the effect of other factors, includingl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(whole foods, micronutrients, dietary patterns, biomarkers)
and lung outcomes (COPD, lung function) support the
broad hypothesis that nutrients with antioxidant proper-
ties improve lung health [10-13], presumably by altering
the oxidant/antioxidant balance in lung tissue. A recent
critical review of the evidence for a causal relation be-
tween nutrition and lung outcomes [9] concluded there
was a “limited/suggestive” role for diet, reflecting that the
majority of studies are cross-sectional. However, most
existing longitudinal studies report protective associations
of antioxidant nutrients and lung outcomes, and there is
strong evidence that the beneficial effects of diet may be
limited to smokers [14]. Given that observational studies
are limited by potential confounding due to lifestyle fac-
tors associated with healthful diets, and given that mea-
sures of diet based on self-report are subject to bias and
have poor precision, experimental studies are needed to
fully understand whether nutrition affects lung function
and its decline with age, particularly in cigarette smokers.
The few randomized controlled trials considering re-
spiratory endpoints other than lung cancer used post-hoc,
secondary analyses [15-17] mainly in special populations
(all heavy smokers, all with vascular disease), did not study
lung function decline, and did not test selenium. Using
the infrastructure of the Selenium and Vitamin E Cancer
Prevention Trial (SELECT) [18], we conducted an ancil-
lary study nested within SELECT to investigate the a
priori hypothesis that supplementation with selenium
and/or vitamin E, two nutrients with antioxidant potential,
would attenuate the annual decline in lung function; we
hypothesized a stronger effect in cigarette smokers given
their higher exposure to inhaled oxidants.
Methods
Study design
The Respiratory Ancillary Study (RAS) was nested within
SELECT [18], a phase 3 randomized, placebo-controlled
double-blind trial of 35,533 men testing whether selenium
(200 μg/d L-selenomethionine) and vitamin E (400 IU/d
all rac-α-tocopheryl acetate) alone and/or in combination
would prevent prostate cancer. SELECT eligibility in-
cluded age ≥55 y (≥50 y in African-Americans), serum
prostate-specific antigen ≤ 4 ng/mL, and no clinical evi-
dence of prostate cancer. SELECT enrolled men in the
United States and Canada between 2001–2004; use of
study supplements stopped on 10/23/2008, after an in-
terim analysis determined that there was no effect and that
further intervention was unlikely to show significant re-
duction in prostate cancer incidence [18]. RAS used a
post-randomization design, due to rapid enrollment in
SELECT relative to the start of RAS; thus, we did not
measure pre-randomization lung function, but we cap-
tured the rate of decline over the intervention periodthrough repeated measurements of lung function. This de-
sign assumed that the intervention effect is reached early
in the study, and is stable over time. To test the hypothesis
that current smokers benefit more from intervention, RAS
enrolled men from the 16 SELECT sites with the greatest
number of current cigarette smokers (Additional file 1:
Table S1). Based on the predicted effect of intervention on
annual FEV1 decline, assuming a 7–10 year follow-up, the
target sample size in RAS was 3000 men.
Participants
Eligibility requirements for registration to RAS included
SELECT registration at one of the 16 SELECT sites with
a high proportion of smokers and adherence to supple-
ments (either active or placebo) at the time of RAS
registration. Each SELECT site invited all eligible current
smokers to RAS and, depending on the number of par-
ticipants at the site, either a random sample or all eli-
gible former and never smokers. Ultimately, men were
registered at their first (5%), second (17%), third (38%)
or fourth (40%) annual SELECT visit. The RAS was ap-
proved by local IRBs at each of the 16 study sites, and
by the Cornell University IRB.
End point assessment
The primary endpoint was annual decline in FEV1; the
secondary endpoint was annual decline in FEF25–75.
Spirometry was assessed at three out of four annual
visits spanning three years. Due to early termination of
SELECT, not all RAS participants completed all sched-
uled pulmonary function tests (PFTs); the endpoint (the
third and final PFT) was available for 57% of partici-
pants. We assume this is an unbiased sample given the
timing of supplementation withdrawal relative to the
timing of a participant’s annual visit is expected to be
random and thus equal across arms.
Pulmonary function testing followed American Thoracic
Society guidelines [19] and used the EasyOne handheld,
flow-sensing spirometer, which has excellent validity and
reliability, and significantly simpler field implementation
in comparison to desktop devices [20]. Only PFTs meeting
criteria for acceptable start and end of test and for reliabil-
ity were included in analyses; further details are provided
in Additional file 1: Table S2).
Statistical analysis
There were three pre-specified main effect comparisons
between each active treatment arm and placebo, with a
P-value threshold of 0.018 to account for the three tests
with a common placebo group. All analyses were intent-
to-treat, and effects were estimated using a linear mixed-
effects regression model incorporating the repeated
measurements of pulmonary function (either FEV1 or
FEF25–75) as the outcome. The model included random
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(time between each PFT and baseline), treatment arm and
its interaction with time (treatment-by-time), age, height,
race and smoking. The treatment-by-time coefficient esti-
mated the effect of treatment on annual rate of decline in
lung function. All RAS men with ≥1 (n = 2920) PFT were
included in the model and contributed to estimates of ef-
fects of age, height, race and smoking, but only men with
≥2 PFTs (n = 1677) were informative for the estimate of
the time-by-treatment coefficient. Missing data were as-
sumed to be missing at random, given very low drop-out
rates. To test whether treatment effects differed by smok-
ing status, models were extended to include the
treatment-by-time-by-smoking interaction terms, and the
significance threshold for the interaction effects was a
nominal P-value of 0.05.
Results
Participants
RAS enrolled 2,920 men (Figure 1) at 16 SELECT sites
between 7/2/2004 and 4/30/2007. RAS eligibility and en-
rollment were blind to intervention arm, and indeed the
number of participants across the four arms was balanced
(Figure 1). RAS experienced minimal attrition, with only
2-3% of men in each intervention group refusing further
RAS and/or SELECT follow-up at some time point afterFigure 1 Flow of participants included in FEV1 analysis by interventio
participants not in contact for 2 years prior to the end of supplemented tim
supplement). 2Refusals defined as withdrawals from SELECT and/or RAS.registration. All participants studied herein had at least
one acceptable PFT, and 56 to 60% of participants in each
arm had repeated PFTs, confirming that repeated measure-
ments for the endpoint assessment were similar by arm.
The mean number of PFTs per participant was 2.3 (SD 1.1;
median 3) with a mean of 36.1 months (SD 4.2) between
first and last PFT (median 35.8 months; range 24 to 52).
Spirometry quality control scores ranged from 3.2 to 3.7
out of maximum score of 4 (Additional file 1: Table S2).
RAS participants had similar distributions of age, race/
ethnicity, education, smoking history and height across
intervention arms (Table 1), confirming that the post-
randomization design yielded four groups balanced on
characteristics. The participants with one PFT were
similar on all baseline characteristics to participants with
repeated PFTs (data not shown); this is consistent with
our expectation because the lack of repeated PFT data
was a function of the date the intervention was with-
drawn, and was not driven by participant choice or par-
ticipant characteristics. Thus, we expect the estimate of
the effect of treatment on lung function decline to be
unbiased. Among participants who completed the final
PFT, the mean time from SELECT registration to a par-
ticipant’s last PFT was 60.4 months (SD 10.8; median
59.8), thus results reflect intervention effects of about
5 years duration.n group. 1Participants lost to follow-up defined as deaths and
e period (March 1, 2009 was used in analyses to proxy the end of
Table 1 Baseline characteristics of study participants†
Characteristic: Placebo
(n = 726)
Vitamin E
(n = 726)
Selenium
(n = 759 )
Vitamin E + selenium
(n = 709)
Age at SELECT randomization, years
Median (interquartile range) 61.7 (57.6–67.5) 61.5 (57.6–66.2) 61.6 (57.7–66.8) 61.5 (57.9–66.6)
50-54 56 (8) 48 (7) 54 (7) 48 (7)
55-64 418 (58) 459 (63) 466 (62) 435 (61)
65-74 212 (29) 190 (26) 208 (27) 192 (27)
≥75 40 (6) 29 (4) 31 (4) 34 (5)
Race/ethnicity
White 510 (70) 491 (68) 515 (68) 489 (69)
African American 165 (23) 177 (24) 189 (25) 162 (23)
Hispanic (non-African American) 20 (3) 32 (4) 22 (3) 22 (3)
Hispanic (African American) 6 (1) 3 (<1) 5 (<1) 5 (1)
Other 25 (3) 23 (3) 28 (4) 31 (4)
Education (highest level)
≤High school graduate or GED 157 (22) 172 (24) 176 (23) 169 (24)
Some college/vocational school 210 (29) 221 (30) 216 (28) 203 (29)
≥College graduate 348 (48) 327 (45) 361 (48) 335 (47)
Unknown/missing 11 (1) 6 (1) 6 (1) 2 (<1)
Smoking status
Never 262 (36) 239 (33) 280 (37) 236 (33)
Current 113 (15) 123 (17) 108 (14) 114 (16)
Former 338 (47) 349 (48) 363 (48) 351 (50)
Ever (Unknown current status)‡ 6 (1) 9 (1) 5 (1) 7 (1)
Unknown 7 (1) 6 (1) 3 (<1) 1 (<1)
Height at SELECT Randomization (cm), mean (standard deviation) 176.8 (8.2) 176.2 (7.8) 176.8 (7.3) 176.4 (7.8)
†Number (percent) unless otherwise noted.
‡Participants who were ever smokers, but did not report current status to differentiate current versus former.
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mined using pill count, compares well to all SELECT
participants [18]. Across the four arms, 87 to 92% of
RAS men were adherent to the selenium supplement (or
matching placebo) in year 1, and 80 to 84% were adherent
in year 5. Similarly, 87 to 92% of RAS men were adherent
to the vitamin E supplement (or matching placebo) in year
1, and 79 to 81% were adherent in year 5. Across all arms,
for the full study period, self-supplementation with non-
study vitamin E and selenium (drop-in rate, assessed by
self-reported use of either supplement) was reported by
≤2.3% and ≤1.2% of participants, respectively.
Rate of decline in pulmonary function
Overall, the distribution of rate of decline in FEV1 was
consistent with expectations of decline, and the mean an-
nual change in FEV1 was −37.5 mL (SD 12.5; Additional
file 1: Figure S1). Compared to never smokers, FEV1 was
363 mL lower in current smokers and annual decline inFEV1 was 6.9 mL/y steeper. In unadjusted analyses of raw
data, compared with the placebo group (Table 3), partici-
pants randomized to intervention experienced an attenu-
ation of between 3 and 6 mL/y in rate of change in FEV1,
but there were no statistically significant differences be-
tween arms. Similarly, for rate of decline in FEF25–75 (mL/
second/y), there were no statistically significant differences
between arms (Table 4).
In linear mixed-effects regression models adjusted for
covariates, the main effect of intervention on rate of de-
cline in lung function was similar to the estimates based
on raw data, considering markers of both volume (FEV1;
Table 3) and flow (FEF25–75; Table 4). Thus, in interven-
tion groups the annual rate of decline in FEV1 was lower
by between 1 and 6 mL/y versus placebo, but effects
were not statistically significant (Table 3). Similarly,
there were no statistically significant main effects of any
intervention on the annual rate of decline in FEF25–75
(Table 4). Sensitivity analyses that considered study site
Table 2 Adherence* to study supplements by pill counts
Placebo Vitamin E Selenium Selenium + vitamin E
Selenium/matching placebo % adherent (range)†
Year 1 (n = 2,920) 92 (87–92) 89 (84–90) 91 (85–91) 87 (82–88)
Year 2 (n = 2,920) 90 (84–91) 87 (81–87) 89 (83–90) 87 (81–88)
Year 3 (n = 2,910) 90 (83–91) 87 (81–88) 89 (82–89) 87 (80–88)
Year 4 (n = 2,887) 85 (78–87) 84 (76–85) 86 (77–87) 87 (77–88)
Year 5 (n = 2,216) 84 (76–85) 80 (73–82) 82 (75–84) 83 (73–85)
Year 6 (n = 901) 82 (72–85) 79 (68–82) 82 (74–84) 86 (75–87)
Vitamin E/matching placebo % adherent (range)†
Year 1 (n = 2,920) 92 (87–92) 89 (84–90) 90 (86–91) 87 (82–88)
Year 2 (n = 2,920) 90 (85–91) 88 (81–88) 88 (82–89) 87 (80–88)
Year 3 (n = 2,910) 88 (82–89) 87 (81–88) 86 (79–87) 86 (78–87)
Year 4 (n = 2,887) 84 (76–85) 81 (74–83) 84 (76–86) 84 (75–86)
Year 5 (n = 2,216) 81 (74–83) 79 (71–81) 81 (74–83) 79 (69–81)
Year 6 (n = 901) 81 (69–83) 76 (66–79) 78 (70–81) 80 (69–82)
*Adherence defined as report of taking ≥80% of study pills; decreasing denominators over time reflect varying amounts of follow-up on participants.
†Percent adherent (range); percent calculated for all participants with data, and ranges estimated by including participants with missing data and assuming
missing were either all non-adherent (low estimate) or all adherent (high estimate).
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(reflecting the length of time on study intervention)
showed similar results.
Effect modification by cigarette smoking
The hypothesis that smoking modifies the effect of supple-
mentation was pre-specified, and models were extendedTable 3 Model-based estimated mean annual decline in FEV1
stratified by cigarette smoking status (Additional file 1: Table
Full sample
All treatment groups:
Unadjusted Adjusted (model-based)
Mean (SD)† Mean (95% CI)††
Placebo −41 (74) −39 (−46, −32)
Vitamin E −34 (75) −33 (−40, −26)
Selenium −37 (74) −38 (−44, −31)
Vitamin E and Selenium −34 (74) −34 (−41, −28)
Marginal Modelsb:
Any Selenium versus Placebo Placebo −39 (−46, −32)
Any Selenium −36 (−41, −31)
Any Vitamin E versus Placebo Placebo −39 (−42, −36)
Any Vitamin E −34 (−38, −30)
Abbreviations: FEV1 forced expiratory volume in the first second, mL milliliter.
*All smoking-stratified treatment vs. placebo comparisons exceeded the P value thr
P = 0.3552, selenium vs. placebo P = 0.4985, vitamin E + selenium vs. placebo P = 0.8
†Mean decline (SD); calculated for men with ≥2 years between first and last pulmon
(placebo), 426 (vitamin E), 416 (selenium) and 417 (vitamin E + selenium) participan
††Model-based estimated mean decline and 95% confidence interval (Additional file
adjusted age, height, race, smoking status, time and tested time x treatment effect
height, race, smoking status, and all two way interactions to test smoking x time x
aP value from mixed-effects linear regression model, with placebo reference group.
bMarginal models combine treatment groups. Any selenium model compares partic
placebo. In a separate model, participants on any vitamin E (vitamin E alone and into estimate intervention effects within categories of ciga-
rette smoking; categories included current, former (quit
prior to trial), and never (lifetime never smoker). In the
placebo arm, expected differences in rate of decline in
FEV1 were confirmed such that the annual decline in
current smokers was 11 to 16 mL/y steeper compared to
former and never smokers (Table 3). Similarly, the annual(mL/year) by treatment group in the full sample, and
s S3 and S4 for model coefficients)
Stratified by smoking status*
P valuea Never smokers Former smokers Current smokers
Mean (95% CI)†† Mean (95% CI)†† Mean (95% CI)††
reference −40 (−52, −29) −35 (−45, −25) −51 (−67, −35)
0.1866 −31 (−42, −20) −36 (−46, −26) −29 (−44, −14)
0.7502 −37 (−48, −26) −38 (−48, −28) −38 (−54, −23)
0.3133 −32 (−44, −20) −32 (−41, −22) −44 (−59, −29)
reference −40 (−52, −29) −35 (−45, −25) −49 (−66, −33)
0.4442 −35 (−43, −27) −35 (−42, −28) −42 (−52, −31)
reference −40 (−51, −29) −34 (−44, −24) −49 (−66, −33)
0.1772 −31 (−40, −23) −34 (−41, −27) −37 (−47, −26)
eshold of 0.05 (all values ≥ 0.25); in current smokers vitamin E vs. placebo
887, any selenium vs. placebo P = 0.8705.
ary function tests where date of last test ≤March 2009; calculated in 418
ts.
1: Tables S3 and S4 for regression model results); main effects models
(effect of treatment on slope); smoking interaction models adjusted age,
treatment interaction (effect of treatment on slope differs by smoking).
ipants on any selenium (selenium alone and in combination with E) to
combination with selenium) are compared to placebo.
Table 4 Model-based estimated annual decline in FEF25–75 (mL/second/year) by treatment group in the full sample,
and stratified by cigarette smoking status (Additional file 1: Tables S3 and S4 for model coefficients)
Full sample Stratified by smoking status
All treatment groups: Unadjusted Adjusted (model-based) P valuea Never smokers Former smokers Current smokers
Mean (SD)† Mean (95% CI)†† Mean (95% CI)†† Mean (95% CI)†† Mean (95% CI)††
Placebo −63 (191) −61 (−78, −43) reference −44 (−73, −15) −58 (−82, −32) −106 (−148, −63)
Vitamin E −45 (201) −46 (−66, −29) 0.2739 −47 (−76, −18) −42 (−67, −17) −59 (−95, −21)
Selenium −67 (200) −64 (−81, −47) 0.6620 −67 (−95, −38) −75 (−100, −49) −45 (−85, −5)*
Vitamin E and Selenium −45 (190) −47 (−64, −29) 0.2719 −71 (−102, −40) −30 (−55, −5) −50 (−90, −10)*
Marginal Modelsb:
Any Selenium versus Placebo Placebo −61 (−78, −43) reference −44 (−73, −15) −57 (−82, −32) −106 (−148, −63)
Any Selenium −56 (−69, −44) 0.7020 −68 (−90, −47) −52 (−70, −34) −47 (−76, −19)*
Any Vitamin E versus Placebo Placebo −61 (−78, −43) reference −44 (−73, −15) −57 (−82, −32) −105 (−147, −63)
Any Vitamin E −46 (−58, −34) 0.2058 −59 (−80, −38) −36 (−54, −18) −54 (−81, −27)*
Abbreviations: FEF25–75 forced expiratory flow rate from the 25
th to 75th percentile of the forced vital capacity, mL milliliter.
*P < 0.05; more specifically, in current smokers selenium vs. placebo P = 0.0219, vitamin E + selenium vs. placebo P = 0.0236, any selenium vs. placebo P = 0.0095,
any vitamin E vs. placebo P = 0.0352, only vitamin E vs. placebo P = 0.1553; all other smoking-stratified treatment vs. placebo comparisons are P > 0.05.
†Mean decline, mL/seconds/year (SD); calculated for men with ≥2 years between first and last pulmonary function tests where date of last test ≤ March 1, 2009;
calculated in 418 (placebo), 426 (vitamin E), 416 (selenium) and 417 (vitamin E + selenium) participants.
††Model-based estimated mean decline, mL/second/year and 95% confidence interval; main effects models adjusted age, height, race, smoking status, time and
tested time x treatment effect (effect of treatment on slope); smoking interaction models adjusted age, height, race, smoking status, and all two way interactions
and tested smoking x time x treatment interaction (effect of treatment on slope within smoking group).
aP value from mixed-effects linear regression model, with placebo reference group.
bMarginal models combine treatment groups. Any selenium model compares participants on any selenium (selenium alone and in combination with E) to
placebo. In a separate model, participants on any vitamin E (vitamin E alone and in combination with selenium) are compared to placebo.
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was more than two-fold that in never smokers (P = 0.0189;
Table 4).
There was no evidence that smoking modified the
effect of intervention on rate of decline in FEV1, and all
P values exceeded the threshold of 0.05. However, for
the FEF25–75 outcome, compared to placebo the annual
rate of decline in FEF25–75 was attenuated in current
cigarette smokers in the selenium arm (P = 0.0219) and
in the combined arm (P = 0.0236). Further models test-
ing any selenium (selenium alone and selenium + vita-
min E, combined) vs. placebo showed that FEF25–75 rate
of decline was decreased by more than half in current
smokers on any selenium compared to current smokers
in the placebo group (P = 0.0095).
Discussion
This is the first randomized trial of selenium and/or
vitamin E intervention that studies the rate of decline in
pulmonary function as the endpoint. This study is im-
portant because it contributes new information about
whether interventions that presumably affect the antioxi-
dant/oxidant balance in lung tissue can ameliorate or at-
tenuate a functional outcome reflecting lung health.
Neither supplementation with selenium nor vitamin E
had statistically significant main effects on rate of de-
cline in FEV1 or FEF25–75. Following our a priori hy-
pothesis that effects are stronger in and/or limited to
current cigarette smokers, there was evidence for adifferential effect of selenium in current smokers for the
flow-related endpoint such that smokers supplemented
with any selenium, either alone or in combination with
vitamin E, had an attenuated rate of decline in FEF25–75.
This randomized trial evidence for an effect of selen-
ium on annual rate of decline in lung function in
smokers is consistent with prior cross-sectional studies
that reported strong positive associations of serum sel-
enium with lung function [14]. An analysis of baseline
bloods collected on a subset of SELECT participants
[18] found that men were rarely low on serum selenium,
where low selenium was defined as ≤ 121.6 ng/mL con-
sistent with prior studies of cancer outcomes [21]. While
this suggests the potential-to-benefit from selenium
intervention in the overall study may be low, the poten-
tial to benefit in smokers is likely to be greater given
prior evidence that selenium concentrations are lower in
smokers [22], and, indeed, this is supported by our
findings.
The pattern of the RAS findings, including the effect
of selenium on flow (FEF25–75) but not volume parame-
ters and the magnitude of the effect sizes, are similar to
the effects of air pollution on lung function reported in
the SAPALDIA study. Based on 11 years of follow-up,
SAPALDIA reported mean annual rate of decline in
FEV1 and FEF25–75 of 35 mL/y (SD 30) and 71 mL/sec-
ond/y (SD 65), respectively [23]. In the RAS placebo
arm, average annual rates of decline were very similar,
although the RAS estimates are more variable given the
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PFTs. SAPALDIA reported that reductions in particulate
matter ≤ 10 microns in diameter (PM10) were associated
with the rate of change in both FEV1 and FEF25–75, but
the strength of the association and the level of statistical
significance were greater for the FEF25–75 outcome [23],
similar to the findings reported herein for supplement
effects in RAS. In current smokers the selenium inter-
vention effect size for annual decline in FEV1 was similar
to the effect size for reducing PM10 exposure by 10 μ/m
3
in SAPALDIA (attenuated FEV1 decline by 4 mL/y).
Greater effect sizes were seen for FEF25–75 in both studies:
in SAPALDIA, reducing PM10 attenuated FEF25–75 decline
by 11 mL/second/y, in RAS selenium supplementation at-
tenuated FEF25–75 decline by 59 mL/second/y. While
FEV1 is less variable than FEF25–75 in cross-sectional stud-
ies [19], longitudinal declines in both endpoints are of
interest and FEF25–75 findings may be salient in smokers
given that changes in flow rates may signal early changes
in small airways function [24]. Although such changes
may not be predictive at the individual level, they may be
informative in the comparison of treatment groups. In
addition, a longitudinal endpoint, which leverages re-
peated measurements per participant, and uses all avail-
able spirometry data on each participant (an approach
that is consistent with two prior studies of longitudinal
change [5,25]), is less affected by variability in comparison
to cross-sectional studies.
Although the vitamin E effect sizes were clinically
meaningful and consistent in effect direction (attenuated
rate of decline) across two pulmonary function mea-
sures, with stronger effects of intervention in current
smokers, the effects did not meet pre-set criteria for
statistical significance. These findings reflect either a
true lack of effect of vitamin E on rate of decline in lung
function, the possibility that baseline vitamin E levels
were high (or at minimum, not deficient) and thus there
was limited potential to benefit from supplementation,
or the possibility that attenuation in decline might occur
only with a longer period of supplementation. While
several past observational studies reported that associa-
tions of vitamin E were limited to smokers [26], such
studies are more likely to be affected by confounding
than the randomized trial findings reported herein.
The Respiratory Ancillary Study (RAS) to SELECT
used a post-randomization design, and participants were
registered to the RAS after active supplementation
began. The primary endpoint was rate of decline in lung
function; absolute differences in lung function due to
the supplements over a fixed period of time were not
calculated because first measurements were obtained
after the participants started taking their supplements.
The design assumes that effects are achieved quickly and
are stable over the supplemented period, which isreasonable given the hypothesis of support for antioxi-
dant function provided by the supplements.
This study measured pre-bronchodilator spirometry,
but the lack of post-bronchodilator spirometry is not a
serious weakness given the primary outcome is rate of
decline, which relies on within-person repeated mea-
surements. A recent study shows similar associations of
pre- and post-bronchodilator spirometry with mortality
[3], which is welcome news given the added participant
burden of conducting post-bronchodilator spirometry in
healthy population studies.
The strengths of RAS include the enrichment of the
study sample with current cigarette smokers, which was
part of the a priori intent to test effect modification, and
the inclusion of a diverse sample (24% African Americans),
which supports inference to broader population groups.
An additional strength was the extensive infrastructure
provided by SELECT, which allowed RAS to be conducted
with efficiencies of cost and effort. SELECT infrastructure
included an online data collection tool, which allowed in-
corporation of web-based uploading of spirometry data on
a weekly basis, and bi-annual meetings of study personnel,
which allowed for optimal training and refresher courses
on spirometry methodology.
A few limitations are worth noting. In the post-
randomization design, we cannot directly estimate
whether the intervention increased FEV1 early in the
supplementation period in smokers on the active study
supplements. This question is important given that prior
studies among individuals with COPD show that some
clinical treatments increase FEV1, but have no effect on
FEV1 rate of decline [27], and in light of the Lung Health
Study, which showed that smoking cessation led to a
small but significant initial rebound in FEV1, followed by
an attenuation in the rate of decline [28]. Our study was
conducted in male participants in the SELECT prostate
cancer prevention trial, thus whether findings apply to
women requires further study. In addition, the design of
SELECT did not vary dose and/or formulation, and did
not consider whether genetic variation might influence
nutrient requirements for optimal health. Finally, the
premature termination of supplements meant that final
pulmonary function test on some participants was col-
lected well after supplements had been discontinued,
and thus analyses were based on fewer participants than
originally planned.
Conclusions
While smoking cessation is the key public health inter-
vention to prevent smoking-related health effects, about
20% of the population continues to smoke [1]. This
study investigated the role of nutritional supplementa-
tion in lung function decline to identify possible inter-
vention strategies to mitigate lung effects in continuing
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cally significant protective effects of selenium, specific-
ally 200 μg/d L-selenomethionine, on rate of decline in
FEF25–75 in current cigarette smokers. Supplementation
with selenium attenuated the annual rate of decline in
FEF25–75 in current cigarette smokers, but neither vita-
min E nor selenium had effects on rate of decline in
FEV1. Further studies are needed to understand whether
intervention effects are modified by baseline selenium
nutriture and/or selenium-related genetic variation [29].
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